Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company MaxiVAX S.A.
DescriptionGM-CSF released over a 1-week period from an encapsulated, genetically modified cell line within a subcutaneously implanted device that is surrounded by irradiated autologous tumor cells
Molecular Target
Mechanism of Action 
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat advanced solid tumors
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today